<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551876</url>
  </required_header>
  <id_info>
    <org_study_id>0653-021</org_study_id>
    <secondary_id>MK0653-021</secondary_id>
    <secondary_id>2006_554</secondary_id>
    <nct_id>NCT00551876</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel, Multicenter Study to Evaluate the Efficacy and Safety of Simvastatin Monotherapy Compared With Simvastatin Plus Ezetimibe (SCH 58235) in Type 2 Diabetic Patients Treated With Thiazolidinediones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the addition of ezetimibe 10 mg daily to ongoing
      20 mg simvastatin daily will reduce LDL Cholesterol to a greater extent than increasing the
      dose of simvastatin to 40 mg daily in Type 2 diabetics treated with Thiazolidinediones (TZD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in fasting LDL-C from baseline to the average of the Week 6/Week 12 measurements</measure>
    <time_frame>6 &amp; 12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Well tolerated in patients in Diabetic patients</measure>
    <time_frame>30 Weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">214</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0653, ezetimibe / Duration of Treatment: 30 Weeks</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women age between 30 and 75 with Type 2 diabetes mellitus who are treated with
             pioglitazone or rosiglitazone

          -  Additionally, patients must have an LDL-C &gt;100 mg/dL at Visit 1 or prior to initiation
             of statin therapy

        Exclusion Criteria:

          -  Patients taking sliding scale insulin, selected lipid lowering medications, oral
             anticoagulants and cyclical sex hormones

          -  Patients with heart disease, kidney disease, liver disease, uncontrolled high blood
             pressure, and insulin dependent diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <reference>
    <citation>Gaudiani LM, Lewin A, Meneghini L, Perevozskaya I, Plotkin D, Mitchel Y, Shah S. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab. 2005 Jan;7(1):88-97.</citation>
    <PMID>15642080</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2007</study_first_submitted>
  <study_first_submitted_qc>October 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2007</study_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis Link</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

